Three Phase 2 Programs PlannedHeatwurx (NASDAQ:PCSA) said the acquisition gives Processa 100% of Vidya’s outstanding equity interests. Gujrathi said VT-7208 is designed as a potentially best-in-class, once-daily BTK inhibitor intended to improve upon the efficacy, safety and convenience of earlier-generation programs. Phase 1 FindingsVidya completed the primary safety and dose-escalation portions of a Phase 1 study of VT-7208. Gujrathi said VT-7208 was generally well tolerated across all evaluated doses, including up to 60 milligrams daily. Processa plans to provide updates as VT-7208 advances through its Phase 2 programs.